

A Localized Macular Rash in an Immunocompromised Patient with Pneumonia and Necrotizing Enterocolitis

Rebecca J Sainato^{1*}, Dina S Parekh¹, Thomas C Newton¹, Michelle S Flores¹, Matthew D Eberly², Nicholas F Logemann³, Nancy C Smith⁴, Hector A Carrero⁴, David M Gianferante¹, Javier A Padial¹ and David R Stagliano¹

¹Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, USA

²Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

³Department of Dermatology, Walter Reed National Military Medical Center, Bethesda, MD, USA

⁴Department of Microbiology, Walter Reed National Military Medical Center, Bethesda, MD, USA

*Corresponding author: Rebecca J Sainato, Department of Pediatrics, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20852, Tel: +301-760-0371; Fax: +301-295-6173; E-mail: rebecca.j.sainato.mil@mail.mil

Received date: May 14, 2017; Accepted date: July 17, 2017; Published date: July 26, 2017

Copyright: © 2017 Sainato RJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

A 21-year-old male with T-cell acute lymphoblastic leukemia (ALL) was admitted for fever and neutropenia. Despite 72 hours of antibiotic therapy, he remained febrile and developed new abdominal and pleuritic chest pain. A computerized tomography (CT) scan demonstrated necrotizing enterocolitis and a left lower lobe pneumonia with early cavitation versus abscess formation. His antimicrobial regimen was broadened to meropenem and voriconazole. On hospital day 5, an asymptomatic rash appeared on his left face consisting of erythematous macules that blanched with pressure. Within 24 hours, the skin lesions expanded and developed a central, non-blanching violaceous hue. Liposomal amphotericin B was added and a biopsy of the rash was obtained. *Mucor* spp was confirmed by tissue culture. Repeat imaging showed interval development of diffusely scattered and innumerable hypodense lesions throughout the liver and spleen, as well as diffuse myositis and within the brain and spine. Care was withdrawn and the patient expired on hospital day 11. Risk factors for developing invasive aspergillosis and mucormycosis are similar. This case illustrates similarities in their clinical presentations, highlights potential gaps in coverage by antifungal agents that are commonly used for empiric coverage, and reviews treatment options.

Keywords: Mucormycosis; Immunocompromised host

Introduction

Aspergillosis and mucormycosis are both molds that can cause invasive infections in immunocompromised hosts, however effective management differs. Although aspergillosis is encountered more commonly, the incidence of mucormycosis may be rising, particularly among those with hematologic malignancies [1].

Case Presentation

We present a 21-year-old male with T-cell acute lymphoblastic leukemia (ALL) who was incidentally noted to be febrile and tachycardic in clinic while neutropenic. The patient had been diagnosed with T-cell ALL 4 months ago and was in remission, receiving consolidation chemotherapy. He had not experienced any infectious complications and was previously healthy. He had not received any antifungal prophylaxis prior to this admission. His absolute neutrophil count (ANC) had been <500 cells/ μ L for 11 days and <100 cells/ μ L for 4 days. Blood cultures were obtained from his port and he was started on cefepime. On hospital day 2 his blood culture revealed Gram-negative rods and so tobramycin was added. The Gram-negative rods were speciated as *Neisseria elongata*. All subsequent blood cultures were negative. Despite 72 hours of antibiotic therapy, he remained febrile and developed new abdominal and pleuritic chest pain. On hospital day 3 a computerized tomography

(CT) scan demonstrated necrotizing enterocolitis and a left lower lobe pneumonia with early cavitation versus abscess formation (Figure 1).




Figure 1: CT scan of the chest demonstrates a 1.8 cm density within the left lower lobe.

His antimicrobial therapy was broadened to meropenem and voriconazole on hospital day 4. Over the next 24 hours, he defervesced. Although supplemental oxygen was added for mild desaturations during sleep, his exam remained stable without tachypnea, increased

work of breathing, or worsening abdominal pain. On hospital day 5, a new asymptomatic rash appeared on his left face consisting of erythematous macules that blanched with pressure (Figure 2).



Figure 2: Localized blanching erythematous macules.



Figure 3: Interval change in rash appearance over 24 hours to non-blanching violaceous papules.

Laboratory investigation revealed persistent profound neutropenia (ANC <100 cells/ μ L), a C-reactive protein of 8.0 mg/L (normal range, <1.0 mg/L), aspartate transaminase of 64 U/L (normal range, 10-40 U/L), and alanine transaminase of 149 U/L (normal range, 7-56 U/L). Serum galactomannan enzyme immunoassay (EIA) and (1-3)- β -D-Glucan testing were pending. Within 24 hours, the skin lesions expanded and developed a central, non-blanching violaceous hue (Figure 3).

No new skin lesions developed. Liposomal amphotericin B was added and a biopsy of the rash was obtained for culture and histopathology. Grocott methenamine silver-stained tissue was significant for innumerable angioinvasive hyphae (Figure 4).




Figure 4: Grocott methenamine silver-stained tissue (200x) significant for innumerable angioinvasive hyphae.

Final Diagnosis

Disseminated mucormycosis.

Hospital Course

The following day fevers returned and respiratory support escalated. He also complained of new left-sided groin pain and weakness of the left lower limb. Ultrasound and Doppler evaluation of the hip and left inguinal region were normal. Magnetic resonance imaging (MRI) of the left hip revealed diffuse myositis within the musculature of the proximal anterior compartments and hyperintense foci within the left femoral head. MRI of the spine was normal. Serum creatine kinase was 160 U/L (normal range, 52-336 U/L). Trans-thoracic echocardiogram was normal. After 48 hours of incubation, his skin culture revealed white colonies on Sabouraud dextrose agar that were identified as *Mucor* spp. Voriconazole was discontinued and caspofungin was added on hospital day 7. Due to increasing respiratory depression with PCA use, the patient was intubated. On hospital day 8, bronchoscopy revealed black, necrotic lung tissue with histopathology also consistent with mucormycosis. MRI of the brain and spine showed 4 rounded intracerebral enhancing lesions concerning for abscesses and enhancement of the occipital sulci around these lesions. Repeat CT imaging of his abdomen and pelvis on hospital day 10 showed diffusely scattered and innumerable 1-3 cm hypodense lesions throughout the liver and spleen. Serum galactomannan EIA and (1-3)- β -D-Glucan testing remained negative throughout his hospital course. Care was withdrawn and patient expired on hospital day 11.

Discussion

In a recent prospective cohort, mucormycosis accounted for more than 10% of invasive mold infections among children [2]. Risk factors for developing aspergillosis and mucormycosis are similar [3,4]. Pneumonia is the predominant clinical presentation for both infections, and there is significant clinical and radiologic overlap, although dissemination favors mucormycosis [3,4]. Given the rarity of isolation via blood culture and absence of serologic markers, tissue

biopsy is almost always necessary for definitive diagnosis of mucormycosis; however, this is often challenging in patients with multiple comorbidities. Voriconazole is a recommended empiric antifungal therapy for neutropenic fever that has less toxicity [5] and improved survival benefit over amphotericin B among those with aspergillosis, [6] but this therapy is not active against mucormycosis [7]. Concern for an increased rate of adverse events without survival benefit [2] likely limits recommendations for empiric combination antifungal therapy, but some high-risk populations may benefit from its judicious use. Isavuconazole is an alternative for treatment of aspergillosis [8] that some suggest could provide equivalent survival benefit to amphotericin B against Mucormycosis [9]. In populations with risk factors, and in presentations that are concerning for invasive mold infection, consider starting an empiric therapy that is effective against both aspergillosis and mucormycosis.

Acknowledgement

The mother of this patient provided written consent for publication of this report.

Conflict of Interest

The authors have no conflicts of interest to declare.

Declaration

The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Army, Department of Defense, or the US Government. Title 17 U.S.C 105 provides that "copyright protection under this title is not available for any work of the United States government." Title 17 U.S.C. 101 defines a United States government work as a work prepared by a military service member or employee of the United States government as part

of that person's official duties. This work was prepared as a part of our official duties.

References

1. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, et al. (2013) Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). *Haematologica* 98: 492-504.
2. Wattier RL, Dvorak CC, Hoffman JA, Brozovich AA, Bin-Hussain I, et al. (2015) A prospective, international cohort study of invasive mold infections in children. *J Ped Infect Dis Soc* 4: 313-322.
3. Jung J, Kim MY, Lee HJ, Park YS, Lee SO, et al. (2015) Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. *Clin Microbiol Infect* 21: e611-688.
4. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP (2005) Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. *Clin Infect Dis* 41: 60-66.
5. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 52: e56-93.
6. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 347: 408-415.
7. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, et al. (2012) How does antifungal pharmacology differ for mucormycosis versus aspergillosis? *Clin Infect Dis* 54: S67-72.
8. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, et al. (2016) Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 63: e1-e60.
9. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, et al. (2016) Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. *Lancet Infect Dis* 16: 828-837.